spacer
home > news
INDUSTRY NEWS AND PRESS RELEASES
 

Strategic Alliance to support efficient, ethical practices in biopharma industry

New collaboration offers broad range of compliance-and risk management strategies in Europe and US to life sciences industry

Hayward, CA and Stockholm, Sweden (07-12-2017) – Two leading drug development and regulatory consultancies announced today that they have formed a new strategic collaboration to help life science companies navigate an increasingly complex global environment. Ethiprax Associates LLC, a leading Compliance and Ethics solutions consultancy based in the US, and NDA Group, a world-leading integrated regulatory/drug development consultancy, are now collaborating to provide the life science industry with truly integrated, trans-Atlantic Compliance-and Risk Management strategies. More>>

 
phone +46 (0)8 590 778 00
email info@ndareg.com
web www.ndareg.com/
email Oxford House Johanneslundsv. 2 S-194 81 Upplands Väsby
 

Charles River Announces Success of Integrated Discovery Project with ENYO Pharma

Capture Compound Mass Spectrometry technology enables target identification

Wilmington, Mass and Lyon, France, Nov. 28, 2017 - Charles River Laboratories International, Inc. (NYSE: CRL) and ENYO Pharma SA today announced the results of a successful collaboration. Together, the companies identified the mode of action of ENYO Pharma’s lead preclinical chemical series, EYP002, using Charles River’s newly acquired, molecular target identification tool: Capture Compound Mass Spectrometry (CCMS) technology. More>>

 
phone +1.877.CRIVER.1
email askcharlesriver@crl.com
web www.criver.com
email Charles River Laboratories International, Inc. 251 Ballardvale Street Wilmington, MA 01887
 

YHEC announces the promotions of Michelle Jenks and Rachael McCool to the role Project Director

Michelle Jenks and Rachael McCool announced as YHEC Project Directors

YHEC is pleased to announce the promotions of Michelle Jenks from the Economic Modelling team and Rachael McCool from the Systematic Reviewing team to the role Project Director. Michelle has a Master’s degree (MSc) in health economics from the University of York and has conducted economic evaluations and systematic reviews for both public and private sector clients. Michelle is the lead modeller in YHEC’s role as an External Assessment Centre for NICE and has also led on a range of economic evaluations conducted for clients within industry, such as cost-utility models and budget impact models. She often leads the development of early economic analyses to inform clinical trial design and pricing strategy. More>>

 
phone +44 (0)1904 323620
email andria.hanbury@york.ac.uk
web www.yhec.co.uk/
email Address: YHEC, Enterprise House, Innovation Way, University of York, York, YO10 5NQ, United Kingdom
 

Navigating the new Clinical Trial Regulation with DIA

For those stakeholders involved with clinical trials in Europe, the new Clinical Trial Regulation to be introduced in 2019 will have a dramatic impact. The aim of the change in regulation is to increase the efficiency of all trials in Europe, as well as promoting research while avoiding the duplication of clinical trials More>>

 
phone +41 61 225 51 36
web www.diahome.org
email Kuechengasse 16 Postfach 4002 Basel, Switzerland
 

Synpromics expands facilities to meet demand for revolutionary gene control technology

It is the first company to move into the new custom-built centre based at the University of Edinburgh’s Easter Bush Campus

Edinburgh, UK, 11th September 2017 - Synpromics Ltd, the leader in gene control and synthetic promoter development, today moves to new world-class facilities at the Roslin Innovation Centre. Synpromics is expanding to meet increasing global demand for its cutting-edge gene control technology, and is the first company to move into the new custom-built centre based at the University of Edinburgh’s Easter Bush Campus. More>>

 
phone +44 (0) 131 651 9662
email info@synpromics.com
web www.synpromics.com
email Roslin Innovation Centre, Easter Bush Campus, Midlothian, EH25 9RG
 

Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences

It will be used in the development of new treatment options for Duchenne muscular dystrophy

Edinburgh, UK – September 20th, 2017 - Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Duchenne muscular dystrophy (DMD). More>>

 
phone +44 (0) 131 651 9662
email info@synpromics.com
web www.synpromics.com
email Roslin Innovation Centre, Easter Bush Campus, Midlothian, EH25 9RG
 

Synpromics announces a research collaboration with GE Healthcare to extend the toolbox for production of biologics

It will see the development of a complex bar-coded library of synthetic promoters

Edinburgh, UK, 4th January 2017 – Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a research collaboration with GE Healthcare to jointly develop customised synthetic promoters optimised for GE Healthcare’s proprietary biopharmaceutical manufacturing platform. More>>

 
phone +44 (0) 131 651 9662
email info@synpromics.com
web www.synpromics.com
email Roslin Innovation Centre, Easter Bush Campus, Midlothian, EH25 9RG
 

Bigneat is awarded the Queen’s Award by Lord-Lieutenant of Hampshire

Bigneat Ltd, winner of a Queen’s Award for Enterprise earlier this year, received their Award from Nigel Atkinson Esq, HM Lord-Lieutenant of Hampshire on 16th October at the Bigneat factory in Waterlooville. More>>

 
 

Oxford Genetics licenses SnapFast™ expression vectors to Twist Bioscience

They will allow Twist Bioscience to clone synthesized DNA for its diverse customer base

November 16, 2017, Oxford, England and San Francisco, US. – Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced today a new licensing agreement with Twist Bioscience Corporation, a company enabling customers to succeed through its offering of rapid, high-quality synthetic DNA. Oxford Genetics will supply Twist Bioscience with its SnapFast™ technology platform to provide a broad range of application-specific expression vectors which Twist Bioscience will use to clone synthesized DNA for its diverse customer base. More>>

 
phone +44 (0) 1865 309 664
web www.oxfordgenetics.com
email Oxford Genetics Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, United Kingdom
 

Fifth Annual Peptides Congress: Registration Now Open

Join us at the forefront of industry innovation at the 5th Annual Peptides Congress

Join us at the forefront of industry innovation at the 5th Annual Peptides Congress, 16-17 April 2018 in London to shape the future of industry discussion. With over 700 peptides in clinical trials and an increasing industry focus on biologics, now more than ever is the time to focus on this revolutionary field! More>>

 
 
 
spacer
News and Press Releases

Strategic Alliance to support efficient, ethical practices in biopharma industry

Hayward, CA and Stockholm, Sweden (07-12-2017) – Two leading drug development and regulatory consultancies announced today that they have formed a new strategic collaboration to help life science companies navigate an increasingly complex global environment. Ethiprax Associates LLC, a leading Compliance and Ethics solutions consultancy based in the US, and NDA Group, a world-leading integrated regulatory/drug development consultancy, are now collaborating to provide the life science industry with truly integrated, trans-Atlantic Compliance-and Risk Management strategies.
More info >>


White Papers

Quality of Steel

Natoli Engineering Company, Inc.

Steel quality is the summation of how well a steel meets its specified chemistry, the cleanliness of the steel or degree to which it is free of impurities or inclusion, homogeneity of the microstructure, grain/carbide size and in some instances if it meets the mechanical requirements for that particular steel. In the design and manufacture of tablet compression tooling, nothing is more important than the quality of the materials being used. The best manufacturing principals maintaining the tightest tolerances will result in tool failure if the initial material quality is poor. Material quality is the fundamental building block upon which all successive value added steps are laid. The majority of all tablet compression tooling is produced from steel and steel quality is the subject of this article.
More info >>

Industry Events

Biotech Showcase 2018

8-10 January 2018, Hilton San Francisco, Union Square, CA 94102 USA

Biotech Showcase™ is an investor and partnering conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement